From our survey

Comparing three ketamine options for St. Charles referrers

Three different treatments share one word, and the patient in your exam room in St. Peters cannot tell them apart. Supervised esketamine, an off-label infusion in a clinic, and a sublingual tablet mailed by a telehealth company all get called ketamine in conversation. They differ in regulatory status, supervision, cost, and the quality of evidence behind them.

The gap is wide because almost nobody starts with any information. When our survey of 443 Midwest adults asked about Spravato, 73 percent said the name was new, and a further 21 percent could not attach any meaning to it. Watch that second group. They have a word and no definition, which is exactly how three things collapse into one. The survey figures are final and describe the public, not clinicians.

Regulatory status, the axis that separates them

Esketamine is the only one of the three with FDA approval for depression. Its label is for adults whose depression outlasted earlier medication trials; it moves through a restricted safety program and is given only at certified sites. Generic ketamine by infusion is off label for depression: legal and common, not a scandal, but no agency has reviewed a protocol, so dosing, session length, and monitoring vary between clinics. At-home oral or sublingual ketamine from a telehealth platform is the least governed. The drug is controlled and the prescriber licensed, and little else is standardized. When you refer, you are choosing among three regulatory environments, not three brands.

Setting and supervision

Esketamine is dosed in the clinic, sprayed by the patient in front of staff, with a monitoring period and blood pressure checks after each dose, and the product stays in the building. IV ketamine is also given on site, the patient in a chair with staff present, though what "present" means is a fair question for any infusion clinic. At-home ketamine moves the dose into the living room, usually with a video check-in and a support person the patient must line up. Between the first and the third, supervision is not slightly different. It is there or it is not.

What the patient does afterward

For esketamine, the label bars driving or operating machinery until the following day and a full night's rest, so every dosing visit needs a ride home. For a working adult commuting on I-70 that is a real scheduling burden, and it is the detail that most often derails an otherwise sound referral. Infusion clinics also send patients home with a driver. At home, the patient is already home, and the sedation unfolds with no one credentialed nearby to notice if it goes further than expected. The convenience is real. So is the trade.

Coverage reality

Only the approved route has a real path to billing as a covered benefit, generally with prior authorization and only where the center participates with the plan. Infusions are mostly cash pay; at-home programs are usually a monthly subscription. Patients feel that difference at once. In our survey, insurance ranked first or second among provider criteria for 85 percent, and 65 percent said coverage would decide or weigh heavily on whether they pursued this at all. Payer mix matters locally too: on a multi-select item, 39 percent of respondents had commercial coverage and 37 percent Medicaid, nearly a tie, while Medicare (23), no insurance (9), and TRICARE (5) made up the rest. For St. Charles County patients, that puts MO HealthNet participation near the top of what to ask a center before you send anyone. Brain Recovery Centers, for one, lays out how its Spravato visits and coverage work in terms a patient can follow.

What the evidence does and does not support

The three routes do not rest on the same literature. Esketamine has registration trials, a label, a defined indication, and mandatory post-dose monitoring built on known risks of sedation, dissociation, and raised blood pressure. IV ketamine for depression has a sizable randomized literature, mostly on short-term effect, with less standardization and thinner maintenance data. At-home oral and sublingual ketamine rests largely on open-label and observational work, much of it from the companies selling the service. None is a cure, none should be pitched as one, and none replaces a workup that asks why the depression has not responded so far.

What patients say they want, against what each option actually is

Our survey also asked about preferred format. The in-person clinic led with 44 percent. Video visits from home took 22 percent, a hybrid that begins in a clinic and shifts home later took 23 percent, with 11 percent indifferent.

Lay that against the regulatory column and an uncomfortable pattern appears. The most convenient model has the least oversight and the weakest evidence, while the model most respondents prefer is the supervised one. They want the safety signal too: for 59 percent of those surveyed, FDA approval would clinch or strongly sway the decision, and 27 percent ranked it among their top two provider criteria. People are asking for a supervised, approved option. They just do not know it exists, which is where the 73 percent comes back around.

A short decision aid for the referring clinician

You do not have to know which route is right. You are well placed to ask a center what a patient will not know to ask.

• Which of the three do you offer, and under what regulatory status for each?
• If you give esketamine, are you certified under its safety program, and who is present during monitoring?
• Who manages a blood pressure spike or a prolonged dissociative reaction?
• Which plans do you take, MO HealthNet included, and how long does prior authorization run?
• What happens if a patient worsens between visits, and what is your after-hours path?

One more thing to keep in front of your patients. If depression turns into thoughts of ending their life, none of this is the next step. Tell them 988 reaches a Lifeline counselor by call or text, day or night, nationwide; that comes before any referral conversation continues.

Methodology

This publisher commissioned the survey behind the figures above and paid for it. The Pollfish consumer panel supplied 443 completes from adults between 18 and 64 in Missouri and nine other Midwest states, with the last response on June 23, 2026. Because it sampled the public and not a patient registry, it reports awareness and preference, never clinical effect. Multi-select questions sum above 100. Pollfish's validation of the panel is complete, and the figures reflect it.